Investigational Drug Information for JNJ-42165279
✉ Email this page to a colleague
What is the drug development status for JNJ-42165279?
JNJ-42165279 is an investigational drug.
There have been 9 clinical trials for JNJ-42165279.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 7th 2015.
The most common disease conditions in clinical trials are Disease, Anxiety Disorders, and Autism Spectrum Disorder. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen-Cilag International NV, and Janssen Pharmaceutica N.V., Belgium.
There is one US patent protecting this investigational drug and twenty-nine international patents.
Summary for JNJ-42165279
| US Patents | 1 |
| International Patents | 29 |
| US Patent Applications | 4 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2015-10-07) |
| Vendors | 51 |
Recent Clinical Trials for JNJ-42165279
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder | Janssen Research & Development, LLC | Phase 2 |
| A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants | Janssen Research & Development, LLC | Phase 1 |
| An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress | Janssen Research & Development, LLC | Phase 2 |
Clinical Trial Summary for JNJ-42165279
Top disease conditions for JNJ-42165279
Top clinical trial sponsors for JNJ-42165279
US Patents for JNJ-42165279
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| JNJ-42165279 | ⤷ Try a Trial | Modulators of fatty acid amide hydrolase | Janssen Pharmaceutica NV (BE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for JNJ-42165279
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| JNJ-42165279 | Australia | AU2011248407 | 2030-05-03 | ⤷ Try a Trial |
| JNJ-42165279 | Brazil | BR112012028179 | 2030-05-03 | ⤷ Try a Trial |
| JNJ-42165279 | Canada | CA2797100 | 2030-05-03 | ⤷ Try a Trial |
| JNJ-42165279 | Chile | CL2012003071 | 2030-05-03 | ⤷ Try a Trial |
| JNJ-42165279 | China | CN102869658 | 2030-05-03 | ⤷ Try a Trial |
| JNJ-42165279 | Cyprus | CY1115248 | 2030-05-03 | ⤷ Try a Trial |
| JNJ-42165279 | Denmark | DK2566861 | 2030-05-03 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
